In the News
LATEST
2021
Aug 16, 2022
No retreat, no surrender: Sosei Heptares takes hit to accelerate pipeline
Aug 2, 2022
With some neuro targets in mind, AbbVie gets Sosei's drug discovery engine churning again
Jul 22, 2022
Sosei Heptares partners with a UK-based cancer research organization to bring its drug to trial
Jan 6, 2022
Verily links up with Sosei Heptares for GPCR drug discovery
Jan 6, 2022
Sosei Heptares and Verily to collaborate on immune-mediated disease treatments
Jan 6, 2022
Sosei and Verily partner on GPCRs; ObsEva touts PhIII data in endometriosis pain - by Paul Schloesser
Nov 22, 2021
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - Biotech Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets - by Ben Adams
Nov 22, 2021
Bouncing back from a PhII flop in schizophrenia, Neurocrine steers into the busy M4/M1 pathway with a $100M cash deal - by John Carroll
Nov 22, 2021
Sosei finds second partner for muscarinic neurology assets in Neurocrine - by Stephen Hansen
Nov 22, 2021
Sosei, Neurocrine ink $2.6B neuropsychiatric collaboration - by Nuala Moran
LATEST
2021